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shaped relationship to weight (BMI) indicating potential
cost offsets by effective weight-loss intervention.
CARDIOVASULAR DISEASES/DISORDERS—
Clinical Outcomes
PCV37
DOES COMPLIANCE WITH ACE-I, DIGOXIN AND
SPIRONOLACTONE INFLUENCE THE TIME TO
EVENT IN PATIENTS WITH HEART FAILURE?
Gwadry-Sridhar F1,Arnold M2,Weaver B1, Guyatt G1
1McMaster University, London, ON, Canada; 2London Health
Sciences Centre, London, ON, Canada
OBJECTIVES: Patients with Heart Failure (HF) are
known to have poor compliance even with medications
that can help reduce mortality and events such as 
readmissions. We wanted to examine whether compliance
with three such medications, primarily ACE-Inhibitors,
Digoxin and Spironolactone would have any impact on
the time to an event in HF patients. An event was deﬁned
as a readmission to hospital, an emergency room visit fol-
lowing a discharge from the index admission or death.
METHODS: Patients with HF who were admitted to the
London Health Sciences Centre were stratiﬁed then ran-
domized to receive either usual care education (U) or an
enhanced educational intervention (I) aimed at improving
compliance that was delivered in hospital, prior to dis-
charge. Compliance data was collected from pharmacy
reﬁll data from baseline over the period of follow-up that
was 12 months. A Cox Regression time-to-event analysis
was run for all patients adjusting for randomization ARM
and then adjusting for the covariates of interest, the
minimum and mean compliance. RESULTS: Seventy-ﬁve
out of 134 patients had an event. There was no difference
in time to event by ARM. The inclusion of the minimum
and mean compliance of each drug individually in the
regression did not result in any signiﬁcant changes in the
time-to-event; however, there was a trend p = 0.082 in
patients who were on spironolactone and had compliance
<0.80. CONCLUSIONS: We can hypothesize that there
may be a differential effect on the time to an event in this
population depending upon the medication. We should be
careful not to group all medication compliance into one
composite number as different medications in HF have
different effects on survival. This data warrants a more
careful assessment of compliance for each HF medication
and a determination of its effect on clinical outcomes of
interest.
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LIPID LOWERING MEDICATIONS 
FOLLOWING CORONARY
REVASCULARIZATION PROCEDURES
Brophy J, Bourgault C, Brassard P
McGill University, Montreal, QC, Canada
OBJECTIVES: Clinical trials have demonstrated
improved outcomes in patients receiving cholesterol low-
ering medications (CLM) following coronary revascu-
larization and clinical guidelines recommend aggressive
cholesterol lowering therapy for patients with established
coronary disease. However, in routine practice, the degree
to which these recommendations are followed and their
impact are unknown. METHODS: Using administrative
databases, we examined the use of CLM in a consecutive
cohort of 11,985 elderly (average age 71.4) patients
undergoing coronary revascularization from 1995 until
1997 in Quebec, Canada. RESULTS: Before revascular-
ization, 30.9% were receiving CLM. After a 3-year
follow-up, 62.8% of cohort survivors had received at
least 1 prescription for CLM. CABG patients had a
decreased probability of receiving CLM compared to PCI
patients (OR .75 95% CI .72–.79). High-risk patients
especially the very elderly (>75) had a signiﬁcantly
decreased probability of receiving CLM (OR .61 95% CI
.57–.66). The most potent predictor of a post-operative
prescription use was pre-operative utilization (OR 7.1
95% CI 6.8–7.5). An adjusted time-dependent analysis
showed that patients receiving CLM had a lower risk of
death (RR 0.61 95% CI 0.52–0.79) or myocardial infarc-
tion (RR 0.78 95% CI 0.64–0.93) than those not exposed
to these drugs. There was no difference in the need for a
repeat revascularization between the groups (RR 1.05
95% CI 0.91–1.20). CONCLUSIONS: CLM were under-
used in this post revascularization population and this
underuse was associated with an increase in adverse 
outcomes.
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A REVIEW OF THE PHARMACOTHERAPEUTIC
MANAGEMENT OF PULMONARY 
ARTERIAL HYPERTENSION
Richard LJ, Howard PA,Thorpe T
Heron Evidence Development LTD, Stevenage,
United Kingdom
Pulmonary arterial hypertension (PAH) is a rare, incur-
able and often fatal disorder of the lung in which pul-
monary artery pressure rises to abnormal levels. It may
either be idiopathic in nature (primary pulmonary hyper-
tension) or a manifestation of many different disorders
(secondary pulmonary hypertension). Current manage-
ment includes prostacyclin vasodilator therapy, and con-
ventional therapy consisting of calcium channel blockers,
anticoagulation, oxygen therapy and diueresis; and newer
agents such as bosentan, an endothelin antagonist. To
date, no systematic review has assessed these interven-
tions. OBJECTIVES: To perform a systematic review of
the medical interventions used in the management of
PAH. METHODS: A literature search of EMBASE and
MEDLINE was performed, and studies matching the pre-
deﬁned inclusion criteria extracted to HTA-standardised
grids and graded using the Jadad score. Data for three
outcome measures survival, exercise capacity and right
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atrial pressure were extracted as these were deemed the
most clinically relevant outcome measures. Where possi-
ble, data was segregated according to intervention, the
type of PAH and the functional class of patients eva-
luated in the studies. RESULTS: The literature search
yielded 1503 abstracts. Of these, 54 were included after
ﬁrst pass assessment. Twenty-eight papers were included
after second pass assessment, and were extracted. The
mean Jadad score was 1.56 (range 0–5). Mean ages for
primary and secondary pulmonary arterial hypertension
were 41 and 47 respectively. Three-year survival rates
were 49% to 76% across all interventions. Mean changes
in right atrial pressure ranged from -6 to 2mmHg, whilst
mean changes in exercise capacity varied from -189 
to 132m. CONCLUSION: The variable quality of the
reviewed articles is partly due to the ethical difﬁculties in
trial design in this disease area. Quantitative comparisons
of the interventions are difﬁcult within the context of this
review, but the homogeneity of the data may make meta-
analysis of the evidence possible.
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COMORBIDITIES CAUSING INCREASING
MORTALITY AT AGES UNDER 65 
IN CARDIOVASCULAR DISEASE 
AND HYPERTENSION
Farquhar IV1, Summers KH2
1Health Services Solutions, Inc, Columbia, MD, USA; 2Eli Lilly
and Company, Indianalpolis, IN, USA
OBJECTIVES: Identify combinations of cancer, cere-
brovascular, diabetes, respiratory, CNS, and infectious
concomitant illnesses in cardiovascular disease causing
increasing risks of dying at ages under 65 and assess sub-
sequent changes in the prevalence of these combinations.
METHODS: Combinations of multivariate linear regres-
sions and standard SAS codes were applied to data drawn
from the 1991–1996 Multiple Causes of Death Files. The
5-year numbers of deaths, cardiovascular-associated, 
and hypertension-associated deaths were 11,056,565,
and 5,486,234 (<65 = 2,769,731), and 904,770 (<65 =
166,007), respectively. RESULTS: During 1991–1996,
mortality rates in individuals with CV disease decreased:
in <65–6% and  65–3%. The prevalence of cardiovas-
cular-associated deaths has decreased from 39.6% to
39.2% of all deaths <65. The following combinations of
comorbidities in individuals <65 with cardiovascular
morbidity demonstrated increasing prevalence (PR), mor-
tality rates (MR) and relative MR of <65/  65: diabetes
(PR -12%, MR -6%, RMR -1.7%); CNS (PR -13%,
MR -8%, RMR -6%); infectious (PR -3%, MR -1%,
RMR -3%). In addition, diabetes in combination with
cerebrovascular, cancers and respiratory comorbidities
caused increased, up to 36%, risk of dying at ages under
65. A 69% (in CV+diabetes) growth of the ischaemic
heart disease case-fatality was the highest increase in 
case-fatality across all primary causes of death. In <65,
mortality rates of hypertension and with diabetes grew
14% and 26% (‘25–29’ -66%), respectively. Among 55
primary causes of death in hypertension, the highest
increase in case-fatality occurred for cns diseases (demen-
tia, psychoses, Alzheimer’s, paralysis), diabetes with renal
manifestations (115%), hypertensive heart (95%), and
respiratory diseases (COPD, pneumonia, asthma, emphy-
sema). CONCLUSION: Although cardiovascular mortal-
ity has decreased overall, disease management for patients
with cns, diabetes, and infectious comorbidities calls for
further research because these groups of patients exhibit
increasing risks of dying at the ages under 65. Related
premature mortality costs and productivity losses will be
presented.
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SCREENING FOR ANEURYSMS AFTER
SUCCESSFUL TREATMENT FOR
SUBARACHNOID HAEMORRHAGE: DO WE
HAVE THE EVIDENCE?
Buskens E1,Wermer M1, van der Schaaf I1, van Hout B1,
Bossuyt P2, Rinkel G1
1UMCU, Utrecht, Netherlands; 2AMC,
Amsterdam, Netherlands
OBJECTIVE: Patients surviving subarachnoid haemor-
rhage (SAH) are at risk for recurrences despite initial suc-
cessful and complete treatment. A simulation model was
used to assess the merits of screening for new aneurysms
and regrowth using CT angiography. METHODS: A 
literature review yielded incidence rates of recurrent
aneurysms (regrowth and de novo), rupture and com-
plications after diagnosis and re-intervention, and the
impact of disabling cerebrovascular events in terms of
(dis-) utility. We used Markov chain Monte Carlo simu-
lation to compare “screening” and “no screening” after
a ﬁrst aneurysmal SAH. Various strategies with screening
intervals of 2, 5 and 10 years were evaluated. We esti-
mated expected quality adjusted life years (QALY’s),
number of SAHs and morbidity and mortality rates for
all strategies, including 95%CI. RESULTS: In cohort
simulations of 10.000 patients the number of QALY’s ten
years after clipping was virtually similar for “screening”
(8.26) and “no screening” (8.32). Screening every two or
ﬁves year did hardly affect the results. Screening every
two years decreased SAH from 1.9% to 0.5% and mor-
tality from 0.9% to 0.6%. The percentage of disabled
patients, however, increased from 0.5% to 1.9%. Similar
trends, i.e., slight QALY loss after screening, were seen
with remaining life expectancy as time horizon. Con-
versely, we observed a slight survival beneﬁt after screen-
ing. Screening after initial treatment with coils resulted in
comparable outcomes. CONCLUSIONS: We lack accu-
rate clinical data on incidence of recurrent aneurysms as
well as subsequent risk of rupture. Also the utility score
attributed to dependency after SAH or another compli-
cation is hardly substantiated. These parameters drive the
results of our modeling analysis. Thus, presently we can
neither recommend nor refute screening patients treated
